Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 6/20 | 0.95 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.95 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.95 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23789507 | 1.00 | CARM1 (0.95) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL14508473 | 1.00 | CARM1 (0.95) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL474948 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL4162680 | 0.95 | CARM1 (0.95) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL9927938 | 0.92 | — | — | |
| Oxalic Acid SCHEMBL9536597 | 0.87 | CARM1 (0.72) | CARM1PRMT6PRMT8PRMT1CA12 | |
| SCHEMBL240714 | 0.86 | — | — | |
| SCHEMBL1045046 | 0.86 | CARM1 (0.79) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL2356698 | 0.85 | CARM1 (0.70) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL23768688 | 0.85 | CARM1 (0.70) | CARM1PRMT6PRMT8PRMT1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807294-B1 | PEPTIDES HAVING INHIBITORY ACTIVITY ON MUSCARINIC RECEPTOR M3 | ACRAF (IT) | 2026-01-14 | — | — | EP | claimed |
| EP-3807293-B1 | PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS | ACRAF (IT) | 2026-01-14 | — | — | EP | claimed |
| US-12377035-B2 | Peptides for inhibiting cholinergic calcitonin gene-related peptide (CGRP) and acetylcholine (ACH) release or inhibiting sensitization-mediated by TRPV1-mediated excitability in sensory neurons and methods of use thereof | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A. (IT) | 2025-08-05 | — | — | US | claimed |
| US-12102705-B2 | Peptides having inhibitory activity on muscarinic receptor M3 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A. (IT) | 2024-10-01 | — | — | US | claimed |
| CN-116854649-A | Gemini quaternary ammonium base type structure directing agent, preparation method thereof, AFX molecular sieve, preparation method thereof and application thereof | 华东理工大学 | 2023-10-10 | — | — | CN | claimed |
| US-20220296489-A1 | PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.P.A. (IT) | 2022-09-22 | — | — | US | claimed |
| US-20220142898-A1 | PEPTIDES HAVING INHIBITORY ACTIVITY ON MUSCARINIC RECEPTOR M3 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.P.A. (IT) | 2022-05-12 | — | — | US | claimed |
| EP-3807293-A1 | PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2021-04-21 | — | — | EP | claimed |
| EP-3807294-A1 | PEPTIDES HAVING INHIBITORY ACTIVITY ON MUSCARINIC RECEPTOR M3 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2021-04-21 | — | — | EP | claimed |
| WO-2019238683-A1 | PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.P.A. (IT) | 2019-12-19 | — | — | WO | claimed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | claimed |
| US-6599370-B2 | Stabilized alkaline compositions for cleaning microelectronic substrates | MALLINCKRODT INC. | 2003-07-29 | — | — | US | claimed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | claimed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | claimed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| EP-0994118-A2 | Complex for the high dielectric film deposition and the method of deposition | ROHM AND HAAS COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | claimed |
| US-5071636-A | Polyaminedithiol compounds; nuclear imaging of regional cerebral blood flow | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1991-12-10 | — | — | US | claimed |
| EP-0322876-A2 | Chelating compounds and their use | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1989-07-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | CARM1 3436/4885PRMT6 1007/4885PRMT8 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.